Acute Agitation And Aggression Treatment Market Report 2026

Acute Agitation And Aggression Treatment Market Overview

• Acute Agitation And Aggression Treatment market size has reached to $6.05 billion in 2025 • Expected to grow to $8.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Rising Dementia Incidence Fuels Growth In Acute Agitation And Aggression Treatment Market • Market Trend: Innovative Solutions For Acute Agitation And Aggression Treatment • North America was the largest region in 2025.

What Is Covered Under Acute Agitation And Aggression Treatment Market?

Acute agitation and aggression treatment refers to the medical and therapeutic interventions to manage and reduce the sudden onset of restlessness, irritability, and hostility in patients. These agitated and aggressive behaviors can be symptoms of various underlying conditions, including psychiatric disorders, neurological disorders, or substance use or withdrawal effects. The main types of acute agitation and aggression treatments are behavioral approaches, environmental interventions, and pharmacologic approaches. The behavioral approach refers to a psychological perspective that emphasizes the scientific study of observable behavior and its environmental determinants. It includes various drugs such as anti-psychotics, benzodiazepines, and others, and is taken through a variety of routes of administration, including oral, intramuscular and others. These are used in treating various indications such as schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation and aggression, alcohol withdrawal and others, by multiple end-users such as hospitals and ambulatory surgical centers, psychiatric care facilities and others.

What Is The Acute Agitation And Aggression Treatment Market Growth Forecast?

The acute agitation and aggression treatment market size is expected to see strong growth in the next few years. It will grow to $8.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing demand for fast-acting therapeutic options, increasing investments in neuropsychiatric drug development, rising use of digital mental health tools, expansion of integrated behavioral care models, stronger focus on patient-centric treatment pathways. Major trends in the forecast period include increasing adoption of rapid-acting pharmacologic treatments, rising focus on personalized psychiatry approaches, growing integration of digital monitoring tools, expansion of emergency behavioral care protocols, enhanced emphasis on patient safety.

What Is The Driver Of The Acute Agitation And Aggression Treatment Market?

The increase in the incidence of dementia is expected to propel the growth of the acute agitation and aggression treatment market going forward. Dementia refers to conditions characterized by impaired memory, cognition, and the capability to manage everyday tasks. A symptom often observed in dementia patients is agitation, manifested through behaviors such as restlessness, repetitive actions, or frequent hand movements. Acute agitation and aggression treatment play a key role in dementia. It reduces the risk of harmful symptoms, improves the patient's quality of life, and manages the underlying cause of the agitation. For instance, in February 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, it was projected that about 401,300 Australians have dementia, and this figure is anticipated to be doubled to reach 849,300 in 2058. Therefore, the increase in the incidence of dementia is driving the growth of the acute agitation and aggression treatment industry.

Key Players In The Global Acute Agitation And Aggression Treatment Market

Major companies operating in the acute agitation and aggression treatment market are Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

Global Acute Agitation And Aggression Treatment Market Trends and Insights

Major companies operating in the acute agitation and aggression treatment market are focusing on developing innovative products, such as a generic version of Zyprexa, to address the needs of patients. Generic Zyprexa is a version of the brand-name drug Zyprexa, which contains the active ingredient olanzapine and is used to treat psychotic conditions. For instance, in September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, launched a generic version of Zyprexa. This atypical antipsychotic drug is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania.

What Are Latest Mergers And Acquisitions In The Acute Agitation And Aggression Treatment Market?

In April 2023, SK Capital Partners LP, a US-based private investment company, acquired Apotex Inc. for an undisclosed amount. With this acquisition, Apotex would allow SK Capital to expand its reach into the generic pharmaceutical market and increase SK Capital's investment in the healthcare industry. Apotex Inc. is a Canada-based generic pharmaceutical producer of drugs for acute agitation and aggression treatment.

What Defines the Acute Agitation And Aggression Treatment Market?

The acute agitation and aggression treatment market includes revenues earned by entities by providing treatment with de-escalation techniques, psychosocial support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute agitation and aggression treatment market also consists of sales of lorazepam, chlorpromazine, and quetiapine API, droperidol, olanzapine, and ziprasidone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Agitation And Aggression Treatment Market Report 2026?

The acute agitation and aggression treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute agitation and aggression treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.